전문 번역가, 번역 회사, 웹 페이지 및 자유롭게 사용할 수 있는 번역 저장소 등을 활용합니다.
metilnaltreksona bromīds
methylnaltrexone bromide
마지막 업데이트: 2014-11-21
사용 빈도: 2
품질:
relistor metilnaltreksona bromīds
relistor methylnaltrexone bromide
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
aktīvā viela ir metilnaltreksona bromīds.
the active substance is methylnaltrexone bromide.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
metilnaltreksona bromīds mēreni izplatās audos.
methylnaltrexone bromide undergoes moderate tissue distribution.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
cyp izozīmi minimāli metabolizē metilnaltreksona bromīdu.
methylnaltrexone bromide is minimally metabolised by cyp isozymes.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
0,6 ml šķīduma (12 mg metilnaltreksona bromīda)
0.6 ml of solution (12 mg methylnaltrexone bromide)
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
viens ml šķīduma satur 20 mg metilnaltreksona bromīda.
one ml of solution contains 20 mg methylnaltrexone bromide.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
metilnaltreksona bromīds izdalās žurku pienā laktācijas periodā.
methylnaltrexone bromide is excreted via the milk of lactating rats.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
katrs 0,6 ml flakons satur 12 mg metilnaltreksona bromīda.
each vial of 0.6 ml contains 12 mg methylnaltrexone bromide.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
relistor ir zāles, kuru aktīvā viela ir metilnaltreksona bromīds.
relistor is a medicine that contains the active substance methylnaltrexone bromide.
마지막 업데이트: 2012-04-10
사용 빈도: 2
품질:
metilnaltreksona bromīds galvenokārt tiek izdalīts nemainītā aktīvās vielas formā.
methylnaltrexone bromide is eliminated primarily as the unchanged active substance.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
metilnaltreksona bromīda aktivitāte ir pētīta pacientiem ar opioīdu izraisītu aizcietējumu.
the activity of methylnaltrexone bromide has been studied in patients with constipation induced by opioids.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
metilnaltreksona bromīds ir selektīvs opioīdu antagonists saistībai ar mu-receptoriem.
methylnaltrexone bromide is a selective antagonist of opioid binding at the mu-receptor.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
metilnaltreksona bromīda kā ceturtējā amīna spēja šķērsot hematoencefālisko barjeru ir ierobežota.
as a quaternary amine, the ability of methylnaltrexone bromide to cross the blood-brain barrier is restricted.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
palielinoties nieru darbības traucējumu smagumam, metilnaltreksona bromīda nieru klīrenss samazinās.
the renal clearance of methylnaltrexone bromide decreased with increasing severity of renal impairment.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
metilnaltreksona bromīds neietekmē citu citohroma p450 (cyp) izozīmu metabolizētu zāļu farmakokinētiku.
methylnaltrexone bromide does not affect the pharmacokinetics of medicinal products metabolised by cytochrome p450 (cyp) isozymes.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
tika analizēti dati par 133 pacientiem (62 saņēma metilnaltreksona bromīdu, 71 placebo).
data from 133 (62 methylnaltrexone bromide, 71 placebo) patients were analysed.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
metilnaltreksona bromīda ietekme uz grūtniecību nav zināma, tādēļ relistor lietošana grūtniecības laikā nav ieteicama.
the effects of methylnaltrexone bromide in pregnant women are not known, and so the use of relistor during pregnancy is not recommended.
마지막 업데이트: 2012-04-10
사용 빈도: 2
품질:
dubultaklajā pētījumā 302 salīdzināja zemādas metilnaltreksona bromīda devu lietošanu katru otro dienu divu nedēļu garumā ar placebo.
study 302 compared double-blind, subcutaneous doses of methylnaltrexone bromide given every other day for 2 weeks versus placebo.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
citi nozīmīgākie metabolisma ceļi ir metabolītu – 2-hidroksi-3-o-metilnaltreksona un
other major metabolic routes are the formation of the metabolites
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질: